Timely topic: premalignant lesions associated with adenocarcinoma of the upper gastrointestinal tract

doi:10.1080/00313020120070830

Pathology

Volume 33, Issue 3, 2001, Pages 271-277

https://doi.org/10.1080/00313020120070830 Get rights and content

Summary

The changing incidence of adenocarcinomas, particularly in the oesophagus and gastric cardia, has led to the rapid expansion of screening programmes aimed at detecting the precursor lesion of dysplasia before adenocarcinoma develops. The pathologist now has an important role in first diagnosing patients at risk for developing dysplasia, and then correctly classifying dysplasia when it occurs. Barrett’s oesophagus has had different diagnostic criteria in previous years but is currently diagnosed by the presence of intestinal metaplasia of any length in the true oesophagus. Intestinal metaplasia confined only to the gastro-oesophageal junction or cardia is of uncertain significance but is probably common, with less risk of progressing to dysplasia or malignancy. In the stomach, patients with autoimmune atrophic gastritis and Helicobacter-associated multifocal atrophic gastritis have an increased risk of adenocarcinoma, but screening protocols are not well-developed compared with those used for Barrett’s oesophagus. Dysplasia of glandular epithelium can be classified using well-described criteria. Low grade dysplasia is the most common type and regresses or remains stable in the majority of patients. High grade dysplasia is more ominous clinically, with a propensity to coexist with or progress to adenocarcinoma.

References (48)

S.J. Spechler et al.
The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett
Gastroenterology
(1996)
W.M. Weinstein et al.
The diagnosis of Barrett’s esophagus: goblets, goblets, goblets
Gastrointest Endosc
(1996)
F.A. Offner et al.
Metaplastic columnar cells in Barrett’s esophagus: a common and neglected cell type
Hum Pathol
(1996)
Y.Y. Chen et al.
Significance of acid-mucinpositive nongoblet columnar cells in the distal esophagus and gastroesophageal junction
Hum Pathol
(1999)
J.A. Boch et al.
Distribution of cytokeratin markers in Barrett’s specialized columnar epithelium
Gastroenterology
(1997)
K. Takubo et al.
Double muscularis mucosae in Barrett’s esophagus
Hum Pathol
(1991)
A.H. Ormsby et al.
Cytokeratin subsets can reliably distinguish Barrett’s esophagus from intestinal metaplasia of the stomach
Hum Pathol
(1999)
R.C. Haggitt
Barrett’s esophagus, dysplasia and adenocarcinoma
Hum Pathol
(1994)
J.J. Ofman et al.
The economic impact of the diagnosis of dysplasia in Barrett’s esophagus
Am J Gastroenterol
(2000)
G.W. Falk
Endoscopic surveillance of Barrett’s esophagus: risk stratification and cancer risk
Gastrointest Endosc
(1999)

B.L. Thurberg et al.

Polypoid dysplasia in Barrett’s esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases

Hum Pathol

(1999)

B.J. Reid et al.

Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets

Am J Gastroenterol

(2000)

S.P. Kilgore et al.

The gastric cardia: fact or fiction?

Am J Gastroenterol

(2000)

S.J. Spechler

The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction

Gastroenterology

(1999)

S.J. Spechler et al.

Prevalence of metaplasia at the gastro-oesophageal junction

Lancet

(1994)

A.H. Ormsby et al.

The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett’s esophagus

Mod Pathol

(2000)

W.M. Weinstein

Precursor lesions for cancer of the cardia

Gastrointest Endosc Clin N Am

(1997)

W.K. Hirota et al.

Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data

Gastroenterology

(1999)

M.P. Bronner

Gastric cancer and intestinal metaplasia

Hum Pathol

(1999)

R.J. Schlemper et al.

Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists

Lancet

(1997)

M. Rugge et al.

Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia

Gastroenterology

(1994)

D.A. Antonioli

Precursors of gastric carcinoma: a critical review with a brief description of early (curable) gastric cancer

Hum Pathol

(1994)

R.H. Riddell

The biopsy diagnosis of gastroesophageal reflux disease, “carditis,” and Barrett’s esophagus, and sequelae of therapy

Am J Surg Pathol

(1996)

S. Nandurkar et al.

Short segment Barrett’s oesophagus: prevalence, diagnosis and associations

Gut

(1997)

Cited by (19)

Temporal trends of esophageal disorders by age in the Cerner Health Facts database
2016, Annals of Epidemiology
Citation Excerpt :
Esophageal adenocarcinoma (EA) incidence has increased approximately 600% over the last 4 decades in the United States [2,3]. Gastroesophageal reflux disease (GERD) is characterized by reflux of gastric contents into the esophagus [4]. It is a common condition that is estimated to affect 10%–20% of adults in Western countries and can cause loss of the native squamous epithelium, followed by the development of Barrett's epithelium (BE) [5].
Esophageal adenocarcinoma incidence has increased approximately 600% over the last 4 decades in the United States. Little research has been conducted on the temporal trends of gastroesophageal reflux disease (GERD) and Barrett's esophagus (BE), yet it is important to establish whether these conditions have also increased with time or differ by age.
The Cerner Health Facts^® database contains information on 35 million patients between 2001 and 2010. GERD, BE, and esophageal cancer (EC) cases were defined using International Classification of Diseases, ninth edition codes. We calculated age-adjusted rates and 95% confidence intervals for GERD, BE, and EC.
In this population, the overall, all-age rate per 100,000 encounters for GERD was 711.9, BE was 21.6, and EC was 6.1. During 2001–2010, GERD rates increased by approximately 50% and EC rates more than doubled, but BE rates declined by approximately 40%. Trends were similar by age, and all rates were higher in Caucasians and males.
These data indirectly support the idea that increased incidence of EC may be partially due to GERD and raise the provocative hypothesis that BE rates may be decreasing possibly as a forerunner of continued stabilization of esophageal adenocarcinoma rates and a possible subsequent decline.
Dietary flavonoid intake and Barrett's esophagus in western Washington State
2015, Annals of Epidemiology
Citation Excerpt :
However, because all existing studies conducted among BE patients have relied on an FFQ [12,38,39], a cohort study would be required, with employment of multiple alternative dietary assessment methods repeatedly over time, to overcome the limitations of existing studies. Such an alternative study design would be inefficient because only 10%–15% of symptomatic GERD patients develop BE in their lifetime [40]. Our study FFQ did not assess dietary supplement use.
Flavonoids, concentrated in fruits and vegetables, demonstrate in experimental studies chemopreventive properties in relation to Barrett's esophagus (BE), a precursor lesion for esophageal adenocarcinoma. One case-control investigation reported an inverse association between isoflavone intake and odds of BE, yet no epidemiologic study has considered other flavonoid classes, which are more commonly consumed by Americans.
We examined intake of total flavonoids, six flavonoid classes, and lignans among case-control study participants in western Washington State. Food frequency questionnaires were self-completed by BE cases with specialized intestinal metaplasia (n = 170) and matched controls (n = 183).
In logistic regression models adjusted for age, sex, body mass index, and energy intake, the odds ratio (OR) for specialized intestinal metaplasia BE associated with anthocyanidin intake was 0.49 (95% confidence interval: 0.30–0.80, for quartiles 2–4 combined vs. quartile 1), for which wine and fruit juice were major dietary sources. More moderate decreased ORs were noted for flavanones, flavonols, isoflavones, and lignans. A modest increased OR was observed for flavones, for which pizza was the main dietary source in our population.
Our findings of an inverse association between anthocyanidins and odds of BE suggest that adequate dietary intake of these compounds may lower risk of this cancer precursor lesion.
HMGA1 is induced by Wnt/β-catenin pathway and maintains cell proliferation in gastric cancer
2009, American Journal of Pathology
The development of stomach cancer is closely associated with chronic inflammation, and the Wnt/β-catenin signaling pathway is activated in most cases of this cancer. High-mobility group A (HMGA) proteins are oncogenic chromatin factors that are primarily expressed not only in undifferentiated tissues but also in various tumors. Here we report that HMGA1 is induced by the Wnt/β-catenin pathway and maintains proliferation of gastric cancer cells. Specific knockdown of HMGA1 resulted in marked reduction of cell growth. The loss of β-catenin or its downstream c-myc decreased HMGA1 expression, whereas Wnt3a treatment increased HMGA1 and c-myc transcripts. Furthermore, Wnt3a-induced expression of HMGA1 was inhibited by c-myc knockdown, suggesting that HMGA1 is a downstream target of the Wnt/β-catenin pathway. Enhanced expression of HMGA1 coexisted with the nuclear accumulation of β-catenin in about 30% of gastric cancer tissues. To visualize the expression of HMGA1 in vivo, transgenic mice expressing endogenous HMGA1 fused to enhanced green fluorescent protein were generated and then crossed with K19-Wnt1/C2mE mice, which develop gastric tumors through activation of both the Wnt and prostaglandin E2 pathways. Expression of HMGA1-enhanced green fluorescent protein was normally detected in the forestomach, along the upper border of the glandular stomach, but its expression was also up-regulated in cancerous glandular stomach. These data suggest that HMGA1 is involved in proliferation and gastric tumor formation via the Wnt/β-catenin pathway.
Photodynamic therapy
2002, Current Problems in Cancer
miR-375-3p/YWHAZ/β-catenin axis regulates migration, invasion, EMT in gastric cancer cells
2019, Clinical and Experimental Pharmacology and Physiology
Histopathology Findings in Patients Undergoing Laparoscopic Sleeve Gastrectomy
2018, Obesity Surgery

View all citing articles on Scopus

View full text